During the first Late-Breaking Trial session of the 2026 ACC Congress held in New Orleans, Saibal Kar, principal investigator of the CHAMPION-AF trial, presented the 3-year results of this groundbreaking study, which were simultaneously published in the NEJM (DOI: 10.1056/NEJMoa2517213).

Aaysha Cader provides her take on sub-analyses of the RETRIEVE AMI trial presented by Jason Leo Walsh at TCT 2025, in San Francisco.

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2025 Scientific Sessions #ACC25

Mirvat Alasnag interviews Michael J. Mack on the PARTNER 3 Low-Risk randomised trial he presented at TCT 2025 in San Francisco.

Nicola Ryan provides her take on the results of TAILORED-CHIP presented by Duk-Woo Park at the ESC Congress 2025 in Madrid.

The first peer-reviewed Open Access journal dedicated to interventional cardiology is now accepting submissions. Contribute to the first edition of EuroIntervention Case Reports by sharing your clinical knowledge.

Philippe Garot describes the EuroPCR 2025 session on left atrial appendage closure (LAAC), which offers a preview of the upcoming new consensus document developed by the Academic Research Consortium.

Lars Wallentin and Stefan James received the Andreas Grüntzig Ethica Award during EuroPCR 2025, on behalf of a wider team of cardiovascular registry experts who have contributed in an extraordinary way to the PCR mission. 

In July 2025, a unilateral decision of the ESC closed a chapter on nearly two decades of successful collaboration between ESC-EAPCI and PCR-Europa - a partnership first established in 2006 and most recently renewed in 2023. 

How should TAVI be adapted to the unique challenges of bicuspid aortic valve disease? In this EuroPCR 2025 discussion, Chiara De Biase, Kentaro Hayashida, and Didier Tchetche explore the key anatomical and procedural considerations for tailoring treatment. From selecting which bicuspid anatomies are suitable for TAVI...

A formal handover took place on Wednesday, 21 May, in Paris during EuroPCR 2025, marking the transition from Stephan Windecker, former Editor-in-Chief, to Robert Byrne, who now assumes the role as the newly appointed Editor-in-Chief of this leading educational resource for interventional cardiologists.

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...

Listen to PCR Chairman William Wijns and Co-Chairmen Jean Fajadet and Bernard Prendergast wish the community a well-deserved relaxing and rejuvenating festive season. They look forward to enjoying your company, friendship and good humour at PCR Courses all around the globe in 2025.

At EuroPCR 2025, Christopher Cook, Philippe Genereux, and Victoria Delgado discuss key results from the EARLY TAVR study.

In asymptomatic patients with severe aortic stenosis, early intervention was associated with significantly less cardiac damage at 2 years, compared to a surveillance strategy that led to extensive damage...

During EuroPCR 2025, Cleverson Zukowski and Pablo Lamelas introduce a landmark initiative: the first clinical guidelines for left main disease specifically developed for Latin America.

Published by the Latin American Society of Interventional Cardiology (SOLACI) and the Interamerican Society of Cardiology (SIAC), these recommendations aim to support...

In this #europcr 2025 roundtable, Lai Wei and Dongming Hou present the latest data on the transfemoral J-Valve for chronic aortic regurgitation.

They begin with the China-DVD study, highlighting that aortic regurgitation is now slightly more prevalent than aortic stenosis in China. The conversation then shifts to...

At EuroPCR 2025, Andreas Baumbach, Christian Juhl Terkelsen and Didier Tchetche reviewed the latest findings from the LANDMARK and Compare-TAVI 1 trials—both focused on the performance of the Myval balloon-expandable valve.

LANDMARK compared Myval and Myval Octacor to leading self-expanding valves in a randomised controlled trial. At...

At EuroPCR 2025, Angela McInerney, Didier Tchétché, and Ole De Backer discuss key results from the SMART and Evolut Low Risk trials. The SMART trial compared balloon-expandable and self-expanding valves in small annulus patients, showing better hemodynamics with the Evolut platform at 2 years. The Evolut...